Damon Race/LinkedIn
Jun 25, 2026, 15:28
Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared a post on LinkedIn:
“Met up with my friends from ReciPharm Advanced Bio at BIO International 2026.
ReciPharm is a wonderful partner in our efforts to advance GENV-HEM, the first gene therapy with durable expression biology for patients with hemophilia A with or without inhibitors.
A special thank you to Greg Behar and Jhomar Marquez.”
Stay updated with Hemostasis Today.
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:52Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety
-
Jun 25, 2026, 14:34Heghine Khachatryan: Hemostasis at the Crossroads of Immunity and Inflammation
-
Jun 25, 2026, 14:30Jean-Jacques Kiladjian: Building the Next Generation of MPN Leaders
-
Jun 25, 2026, 14:29Shadi Tabibian: Navigating Modern Diagnosis and Individualized Care in Hemophilia A and B
-
Jun 25, 2026, 14:17Kuhu K.: We Need to Break the Silence on Mental Health After Stroke